NCT02836795已完成1 期
A Phase I, Open Label, Single Center and Dose Escalation Study Investigating Tolerance and Pharmacokinetics of Single and Multiple Doses of Recombinant Humanized Anti-PD-1 Monoclonal Antibody for Injection in Patients With Advanced Solid Tumors
Shanghai Junshi Bioscience Co., Ltd.1 个研究点 分布在 1 个国家目标入组 35 人开始时间: 2016年4月最近更新:
适应症
干预措施
相关药物
试验速览
- 阶段
- 1 期
- 状态
- 已完成
- 发起方
- 入组人数
- 35
- 试验地点
- 1
- 主要终点
- Number of participants with treatment-related adverse events as assessed by CTCAE v4.0
研究概览
简要总结
This is a mono-center, open-label, phase 1 study evaluating the humanized anti-PD-1 antibody JS001, as a monotherapy in patients with advanced melanoma or urological cancers who have failed in routine systemic treatment. The study will be conducted in 2 parts: dose escalation and cohort expansion to investigate tolerability and efficacy.
详细描述
This is a mono-center, open-label, phase 1 study evaluating the humanized anti-PD-1 antibody JS001, as a monotherapy in patients with advanced solid tumor (melanoma or urological cancers) who have failed in previous routine systemic treatment. The study will be conducted in 2 parts: dose escalation and cohort expansion. In the first part, nine patients are injected with different dosage of the humanized anti-PD-1 antibody (1mg/kg or 3mg/kg or 10mg/mg, three patients in one group ) once and observed carefully in the following 4 weeks. If no dose-limiting toxicity (DLT) occurs, then they are injected every 2 weeks until disease progresses or unacceptable toxicity occurs. This part is to confirm DLT, maximum tolerated dose (MTD) and recommended dose (RD). In the second part, 6-12 patients are enrolled in each dosage group and injected with the humanized anti-PD-1 antibody every 2 weeks until disease progresses or unacceptable toxicity occurs. This part is to further analyze safety and efficacy of the humanized anti-PD-1 antibody.
研究设计
- 研究类型
- Interventional
- 分配方式
- Na
- 干预模型
- Single Group
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 70 Years（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Male and Female aged 18 to 70 years are eligible;
- •Eastern Cooperative Oncology Group (ECOG) performance status score of 0 or 1
- •Histologic diagnosis of unresectable melanoma or urological cancer. Have failed at least 1 prior routine regimen for metastatic disease, or failed to tolerate the toxicity, or lack of any routine regimens.
- •Providing with tumor specimen (for testing the expression of PD -L1 and the infiltrating lymphocytes);
- •At least 1 measurable lesion (only 1 measurable lymph node lesion is excluded) (routine CT scan >=20mm, spiral CT scan >=10mm, no prior radiation to measurable lesions) Predicted survival >=6 months;
- •Brain or meningeal metastases must be disposed with surgery or radiation, and be stable clinically for at least 8 weeks (prior systemic steroids was allowed, but concurrent administration of systemic steroids with the study drug is excluded).
- •Screening laboratory values must meet the following criteria（within past 14 days）:
- •hemoglobin ≥ 9.0 g/dL neutrophils ≥ 1500 cells/ µL platelets ≥ 100 x 10^3/ µL total bilirubin ≤ 1.5 x upper limit of normal (ULN) aspartic transaminase (AST) and alanine transaminase (ALT) ≤ 2.5 x ULN without, and ≤ 5 x ULN with hepatic metastasis serum creatinine ≤1╳ULN，creatinine clearance >50ml/min (Cockcroft-Gault equation)
- •Without systemic steroids within past 4 weeks
- •Males or female of childbearing potential must: agree to use using a reliable form of contraception (eg, oral contraceptives, intrauterine device, control sex desire, double barrier method of condom and spermicidal) during the treatment period and for at least 12 months after the last dose of study drug.
- •Must have read, understood, and provided written informed consent voluntarily. Willing to adhere to the study visit schedule and the prohibitions and restrictions specified in this protocol.
排除标准
- •Hypersensitivity to recombinant humanized anti-PD-1 monoclonal Ab or its components.
- •Prior treatment with mAb within past 3 months (locally administration excluded)
- •Prior antitumor therapy (including corticosteroids and immunotherapy) or participation in other clinical trials within past 4 weeks, or have not recovered from toxicities since the last treatment;
- •Pregnant or nursing
- •Abnormal Blood coagulation
- •Positive tests for HIV, HCV, HBsAg or HBcAb with positive test for HBV DNA (>500IU/ml)
- •History with pulmonary tuberculosis;
- •Patients with any active autoimmune disease or a documented history of autoimmune disease, or history of syndrome that required systemic steroids or immunosuppressive medications, such as hypophysitis, pneumonia, colitis, hepatitis, nephritis, hyperthyroidism or hypothyroidism.
- •Severe, uncontrolled medical condition that would affect patients' compliance or obscure the interpretation of toxicity determination or adverse events, including active severe infection, uncontrolled diabetes, angiocardiopathy (heart failure > class II NYHA, heart block >II grade, myocardial infarction, unstable arrhythmia or unstable angina within past 6 months, cerebral infarction within past 3 months) or pulmonary disease ( interstitial pneumonia, obstructive pulmonary disease or symptomatic bronchospasm).
- •Evidence with CNS disease.
- •Prior treatment with bone marrow stimulating factors，such as CSF (colony stimulating factor), EPO (erythropoietin), within past 1 weeks
- •Prior live vaccine therapy within past 4 weeks.
- •Prior major surgery within past 4 weeks (diagnostic surgery excluded).
- •Psychiatric medicines abuse without withdrawal, or history of psychiatric illness.
- •Prior malignancy active within the previous 5 years except for locally curable cancers that have been apparently cured, such as basal cell skin cancer or carcinoma in situ of the cervix.
- •Underlying medical condition that, in the Investigator's opinion, would increase the risks of study drug administration or obscure the interpretation of toxicity determination or adverse events.
研究组 & 干预措施
humanized anti-PD-1 monoclonal antibody Toripalimab
Experimental
humanized anti-PD-1 monoclonal antibody is to be injected intravenously 1mg/kg or 3mg/kg or 10mg/kg until disease progresses or unacceptable tolerability occurs.
干预措施: humanized anti-PD-1 monoclonal antibody Toripalimab (JS001) (Biological)
结局指标
主要结局
Number of participants with treatment-related adverse events as assessed by CTCAE v4.0
时间窗: 1.5 years
次要结局
- Duration of Response (DOR) by irRC and RECIST 1.1(3 years)
- Time to response (TTR) by irRC and RECIST 1.1(3 years)
- Progression-free survival(PFS) by irRC and RECIST 1.1(3 years)
- Overall survival (OS) by irRC and RECIST 1.1(3 years)
- Maximum Plasma Concentration (Cmax) after single dose injection of Anti-PD-1 Monoclonal Antibody (mAb)(1.5 years)
- Minimum Plasma Concentration (Cmin) of steady state after multiple dose injection of Anti-PD-1 mAb(1.5 years)
- Average Plasma Concentration (Cav) of steady state after multiple dose injection of Anti-PD-1 mAb(1.5 years)
- PD-1 receptor occupancy of blood(1.5 years)
- Disease Control Rate (DCR) by irRC and RECIST 1.1(3 year)
- Peak Time (Tmax) after single dose injection of Anti-PD-1 mAb(1.5 years)
- t1/2 after single dose injection of Recombinant Humanized Anti-PD-1 mAb(1.5 years)
- Apparent volume of distribution (V) after single dose injection of Anti-PD-1 mAb(1.5 years)
- Plasma clearance (CL) after single dose injection of Anti-PD-1 mAb(1.5 years)
- degree of fluctuation (DF) of steady state after multiple dose injection of Anti-PD-1 mAb(1.5 years)
- Objective Response Rate (ORR) by irRC and RECIST 1.1(3 years)
- Area Under the Curve (AUC) after single dose injection of Anti-PD-1 mAb(1.5 years)
- Apparent volume of distribution of steady state (Vss) after multiple dose injection of Anti-PD-1 mAb(1.5 years)
研究者
研究点 (1)
Loading locations...
相似试验
已完成
1 期
Safety and Tolerability of Recombinant Humanized Anti-PD-1 Monoclonal Antibody for Patients With Advanced Breast CancerBreast CancerNCT02838823Shanghai Junshi Bioscience Co., Ltd.20
Unknown
2 期
Safety and Efficacy of Recombinant Humanized Anti-PD-1 mAb for Patients With Locally Advanced or Metastatic MelanomaMetastatic MelanomaAdvanced MelanomaNCT03013101Shanghai Junshi Bioscience Co., Ltd.128
Unknown
2 期
Safety and Efficacy of Toripalimab for Patients With Locally Advanced or Metastatic Bladder Urothelial CarcinomaBladder Urothelial CarcinomaNCT03113266Shanghai Junshi Bioscience Co., Ltd.370
招募中
2 期
Study of Anti-PD-1/PD-L1 Antibody Plus Apatinib as Second-Line Treatment of Advanced Esophageal Squamous CellEsophageal CancerNCT03736863The First Affiliated Hospital of Zhengzhou University125
尚未招募
2 期
A Phase II Study for 609A in the Treatment of Advanced Undifferentiated Pleomorphic SarcomaSarcoma, Soft TissueNCT05193214Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd.30